TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06750432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMN310
Description: A humanized immunoglobulin G1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMN310
Description: A humanized immunoglobulin G1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% NaCl 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% NaCl 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% NaCl 100 mL
Study: NCT04788095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in an app-based mindfulness program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06761703

Intervention type: DEVICE
Intervention: TAP® Micro Select Device (Touch Activated Phlebotomy)
Description: The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.
Study: NCT06763835

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood is drawn to test for specific biomarkers
Description: After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood is drawn to test for specific biomarkers
Description: After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.
Study: NCT06766981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration with Articain 4%
Description: The experimental group of patients that are diagnosed for tooth extraction of mandibular 1st. molar will undergo extraction using an infiltration technique for local anaesthesia. In contrast to the conventional group that will receive Inferior alveolar nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Alveolar Nerve Block
Description: This group will receive a conventional inferior alveolar nerve block (IANB) technique with 2% lidocaine with epinephrine (1:80,000) for tooth extraction.
Study: NCT06767137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is a gold-standard, evidence-based treatment combining techniques to improve the clinical symptomatology of insomnia. Delivered in six 90-minute group sessions over six weeks, it includes: sleep education (i.e. understanding sleep mechanisms and influencing factors), bedtime restriction (i.e. aligning bedtimes with reported sleep duration), stimulus control (i.e. getting out of bed when unable to sleep), cognitive therapy (i.e. addressing dysfunctional sleep beliefs), relaxation techniques (i.e. using methods like progressive muscle relaxation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime restriction (BRT)
Description: Bedtime Restriction Therapy (BRT): A behavioral intervention aimed at improving the clinical symptomatology of insomnia by aligning time spent in bed with reported sleep duration. Participants attend four 60-minute group therapy sessions over six weeks. The intervention includes: setting individualized sleep windows based on sleep diaries, regular adjustment of sleep schedules to enhance sleep pressure, group discussions to address implementation challenges and maintain motivation.~BRT focuses exclusively on bed time restriction without additional cognitive or relaxation components, making it a simplified, resource-efficient approach to treating insomnia.
Study: NCT06764940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone in combination with capecitabine
Description: Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study: NCT06766318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group A will receive cryo-ultrasound therapy combined with conventional physical therapy for two months
Description: Cryo-ultrasound therapy combines two therapeutic methods: cryotherapy (using cold) and ultrasound (using sound waves). The ultrasound component provides a therapeutic heating effect, improving blood circulation and tissue flexibility, while the cold component reduces pain and inflammation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER therapy
Description: group B will receive LASER therapy combined with conventional physical therapy.
Study: NCT06766383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPT-simulated patients
Description: GPT-simulated patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional role-playing
Description: traditional role-playing
Study: NCT06775041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.

Intervention type: DRUG
Group type: OTHER
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Study: NCT06770790

Intervention type: OTHER
Intervention: strain echocardiography
Description: HR, MAP, SBP, and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Two transthoracic 2D echocardiographic examinations will be performed immediately before and 15 minutes after TEA. The examinations include apical four-, two-, and three-chamber projections, mitral and aortic Doppler flow velocities. Standard measurements of left ventricular systolic function include left ventricular volumes (indexed to body surface area, BSA), left ventricular ejection fraction (LVEF) according to the modified Simpson rule, time and velocity integral in the left ventricular outflow tract (TVI-LVOT), and stroke volume (SV) (= π x LVOT radius2 x TVI-LVOT). Stroke volume index (SVI) will be calculated as SV/BSA. Mitral and aortic Doppler flow profiles, left ventricular isovolumetric relaxation time, maximum flow velocity will be recorded for m
Study: NCT06771921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1078
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1078
Description: Specified dose on specified days.
Study: NCT06770387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhealth
Description: mobile application for postoperative period
Study: NCT06773078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intake group
Description: Intake of a breakfast containing the foods of interest avocado (80gr), corn tortilla (60 gr), nopal (200 gr), guava (108 gr), mango (100 gr), amaranth (14 gr).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Average intake group
Description: Intake of a breakfast containing the foods of interest avocado (40gr), corn tortilla (30 gr), nopal (100 gr), guava (54 gr), mango (50 gr), amaranth (7 gr).
Study: NCT06770088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vnacicizumab
Description: Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
Study: NCT06772129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Studies have been reviewed and no lavender aromatherapy has been found to be used for delirium.
Study: NCT06770504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YTS109
Description: In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.
Study: NCT06770868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific reconstruction plate for patients suffering from mandibular segmental defects
Description: Patients with mandibular segmental defect including coronoidectomy managed with patient specific reconstruction plate with custom made temporalis tendon enthesis
Study: NCT06771895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise and nutritional intervention
Description: The intervention consists of a combined exercise and nutritional intervention. All subjects will perform 20 weeks of supervised resistance and endurance type exercise training 2 to 3 days per week. Leg press, leg extension, calf raises, chest press, shoulder press, horizontal row and vertical lateral pull exercise will be performed on weightlifting machines in addition to cycling on an ergometer. The dietary intervention aims to attain a diet that comprises sufficient protein, with a minimum of 1.2 g/kg bodyweight/day distributed as 25-30 g protein per main meal, and is otherwise in line with the Dutch Healthy Diet guidelines. In support, subjects will consume a daily multi-nutrient supplement containing leucine-enriched whey protein, vitamin D, omega-3 long chain polyunsaturated fatty acids (n-3 lcPUFA), calcium, choline and pre- and probiotics, which will be ingested pre-sleep. There will be an additional supplement intake moment following each training session.
Study: NCT06774131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-104
Description: UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
Study: NCT05560932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB-motivational interviewing (MI) techniques (IMB-MI)
Description: The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
Study: NCT05334446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Effect of the Mobile Application
Description: This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control.
Study: NCT06770634

Intervention type: OTHER
Intervention: Bioelectrical Impedance Analysis
Description: With Bioelectrical Impedance Analysis, fat, muscle and water ratio and lean mass are calculated in addition to the patient's body weight.

Intervention type: OTHER
Intervention: Bioelectrical Impedance Analysis
Description: With Bioelectrical Impedance Analysis, fat, muscle and water ratio and lean mass are calculated in addition to the patient's body weight.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Measurement of subcutaneous fat tissue thickness from mid-thigh, pretibial, lateral leg and supramalleolar regions with ultrasound.The average of two measurements taken from the same area will be recorded.According to these measurements; 12-15 mm = mild lipedema or lipohyperplasia, 15-20 mm = moderate lipedema, \>20 mm = significant lipedema, \>30 mm = severe lipedema.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Measurement of subcutaneous fat tissue thickness from mid-thigh, pretibial, lateral leg and supramalleolar regions with ultrasound.The average of two measurements taken from the same area will be recorded.According to these measurements; 12-15 mm = mild lipedema or lipohyperplasia, 15-20 mm = moderate lipedema, \>20 mm = significant lipedema, \>30 mm = severe lipedema.
Study: NCT06771141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Video Session
Description: This intervention involves a 10-minute virtual reality (VR) video session designed to reduce pre-procedural anxiety and promote relaxation in pediatric patients. The video immerses participants in a calming virtual environment with interactive and visually engaging content tailored for children. It is administered prior to the endoscopy procedure to help manage anxiety and stabilize vital signs, such as blood pressure, heart rate, and oxygen saturation. The VR session serves as a non-pharmacological approach to anxiety management during medical procedures.
Study: NCT06771713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Pain Reprocessing Therapy (BPRT)
Description: Participants will have three 90-minute behavioral intervention sessions over a 3-week period, completing 35 days of brief daily assessments, and one additional set of questionnaires.~Participants will also complete study questionnaires at 1, 2, 3, and 6 months after attending the 3 behavioral intervention sessions.
Study: NCT06771102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope Gastro
Description: CE-marked single-use gastroscopes from Ambu are used in the single-use group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic gastroscopes, Olympus
Description: Reusable gastroscopes from Olympus are used in the reusable group.
Study: NCT06774404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of FreeStyle Libre 14 day Flash Glucose Monitoring System
Description: Women with GDM in the intervention arm will use Flash Glucose Monitoring (FGM) from diagnosis until the end of pregnancy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Only using SMBG
Study: NCT06772025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No investigational study intervention
Description: No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 150 mL) and urine samples and of available clinical data are the only activities performed in addition.
Study: NCT06771830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric eCART
Description: Integration of the pediatric version of electronic Cardiac Arrest Risk Triage as a clinical decision support tool within Epic for use by clinicians
Study: NCT06772324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group
Description: Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORSPAN Buprenorphine Transdermal Patchs for Lower dose group
Description: The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORSPAN Buprenorphine Transdermal Patchs for higher dose group
Description: The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
Study: NCT06773559

Intervention type: DIAGNOSTIC_TEST
Intervention: plantar pressure, gait and static balance analysis
Description: Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.

Intervention type: DIAGNOSTIC_TEST
Intervention: plantar pressure, gait and static balance analysis
Description: Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.

Intervention type: DIAGNOSTIC_TEST
Intervention: plantar pressure, gait and static balance analysis
Description: Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.

Intervention type: DIAGNOSTIC_TEST
Intervention: trunk posture analysis
Description: Trunk posture analysis was performed using Diers Formetric 4D.

Intervention type: DIAGNOSTIC_TEST
Intervention: trunk posture analysis
Description: Trunk posture analysis was performed using Diers Formetric 4D.

Intervention type: DIAGNOSTIC_TEST
Intervention: trunk posture analysis
Description: Trunk posture analysis was performed using Diers Formetric 4D.
Study: NCT06770231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single drill system
Description: New system for drilling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single drill system
Description: New system for drilling
Study: NCT06770582

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional blood and urine sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06771622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB101
Description: QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB101
Description: QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB101
Description: QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB101
Description: QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV on Day 1, cycled every 21 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV on Day 1, cycled every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV on Day 1, cycled every 21 days
Study: NCT06073483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toumai Endoscopic surgery System
Description: 5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
Study: NCT05942781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular training using VR followed by Control
Description: A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control followed by Vestibular training using VR
Description: Group two will follow the reverse sequence.
Study: NCT05006300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topialyse Baume Barrière
Description: Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topialyse Baume Barrière
Description: Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
Study: NCT05307913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP
Description: PEEP setting according to EIT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table-guided PEEP
Description: PEEP setting according to the lower PEEP/FiO2 table